Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate Efficacy and Safety of Pazopanib Versus Sunitinib for the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma - A Substudy to VEG108844
Brief Summary: This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior systemic therapy for advanced or metastatic RCC.


Options:
A: Arm Label: Immediate nephrectomy; Type: ACTIVE_COMPARATOR; Interventions: Genetic: gene expression analysis, Other: biologic sample preservation procedure, Other: laboratory biomarker analysis, Procedure: therapeutic conventional surgery | Arm Label: Deferred nephrectomy; Type: EXPERIMENTAL; Interventions: Procedure: timing of surgery, Genetic: gene expression analysis, Other: biologic sample preservation procedure, Other: laboratory biomarker analysis | Intervention Type: PROCEDURE; Name: timing of surgery; Assigned to Arm(s): Deferred nephrectomy | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): Deferred nephrectomy, Immediate nephrectomy | Intervention Type: OTHER; Name: biologic sample preservation procedure; Assigned to Arm(s): Deferred nephrectomy, Immediate nephrectomy | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Deferred nephrectomy, Immediate nephrectomy | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): Immediate nephrectomy
B: Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: Arm A (bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study | Arm Label: Arm B (bevacizumab and temsirolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Temsirolimus | Arm Label: Arm C (bevacizumab and sorafenib tosylate); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate | Arm Label: Arm D (sorafenib tosylate and temsirolimus); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate, Drug: Temsirolimus | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Arm B (bevacizumab and temsirolimus), Arm D (sorafenib tosylate and temsirolimus)
D: Arm Label: tivozanib (AV-951); Type: EXPERIMENTAL; Interventions: Drug: tivozanib (AV-951) | Arm Label: sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: tivozanib (AV-951); Assigned to Arm(s): tivozanib (AV-951) | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): sorafenib

Answer: B